{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:21:11Z","timestamp":1789608071908,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"Horizon 2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["956851"],"award-info":[{"award-number":["956851"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejps.2024.106845","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T01:48:25Z","timestamp":1720144105000},"page":"106845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Exploring the interactions of JAK inhibitor and S1P receptor modulator drugs with the human gut microbiome: Implications for colonic drug delivery and inflammatory bowel disease"],"prefix":"10.1016","volume":"200","author":[{"given":"Alessia","family":"Favaron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"McCoubrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmi Prasanna","family":"Nandiraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shorthouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gaisford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul W.","family":"Basit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2047-5025","authenticated-orcid":false,"given":"Mine","family":"Orlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2024.106845_bib0002","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.tca.2012.12.005","article-title":"Microbial growth and isothermal microcalorimetry: growth models and their application to microcalorimetric data","volume":"555","author":"Braissant","year":"2013","journal-title":"Thermochim. Acta"},{"issue":"1","key":"10.1016\/j.ejps.2024.106845_bib0003","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13059-018-1568-0","article-title":"KrakenUniq: confident and fast metagenomics classification using unique k-mer counts","volume":"19","author":"Breitwieser","year":"2018","journal-title":"Genome. Biol"},{"issue":"6","key":"10.1016\/j.ejps.2024.106845_bib0004","first-page":"17","article-title":"Plummer NT. part 1: the human gut microbiome in health and disease","volume":"13","author":"Bull","year":"2014","journal-title":"Integr. Med. (Encinitas)"},{"issue":"1","key":"10.1016\/j.ejps.2024.106845_bib0005","doi-asserted-by":"crossref","first-page":"18218","DOI":"10.1038\/s41598-023-45534-0","article-title":"Age and severity-dependent gut microbiota alterations in Tunisian children with autism spectrum disorder","volume":"13","author":"Chamtouri","year":"2023","journal-title":"Sci. Rep"},{"key":"10.1016\/j.ejps.2024.106845_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1174832","article-title":"Insight into gut dysbiosis of patients with inflammatory bowel disease and ischemic colitis","author":"Dahal","year":"2023","journal-title":"Front. Microbiol"},{"issue":"1","key":"10.1016\/j.ejps.2024.106845_bib0007","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrmicro3552","article-title":"Gut biogeography of the bacterial microbiota","volume":"14","author":"Donaldson","year":"2016","journal-title":"Nat. Rev. Microbiol"},{"issue":"23","key":"10.1016\/j.ejps.2024.106845_bib0008","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.3390\/jcm10235660","article-title":"Efficacy, safety and future perspectives of JAK inhibitors in the IBD treatment","volume":"10","author":"Dudek","year":"2021","journal-title":"JCM"},{"key":"10.1016\/j.ejps.2024.106845_bib0001","unstructured":"FDA, (2021). requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions.:7."},{"key":"10.1016\/j.ejps.2024.106845_bib0009","unstructured":"European Medicines Agency. Olumiant: EPAR - public assessment report . [cited 2024 Jun 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/olumiant-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.ejps.2024.106845_bib0010","unstructured":"European Medicines Agency. Xeljanz: EPAR - public assessment report [Internet]. [cited 2024 Jun 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/xeljanz-epar-public-assessment-report_en.pdf-0."},{"issue":"1","key":"10.1016\/j.ejps.2024.106845_bib0011","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat. Rev. Microbiol"},{"key":"10.1016\/j.ejps.2024.106845_bib0012","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2024.04.024","article-title":"Can in vitro\/in silico tools improve colonic concentration estimations for oral extended-release formulations? A case study with upadacitinib","volume":"370","author":"Favaron","year":"2024","journal-title":"J. Contr. Rel"},{"key":"10.1016\/j.ejps.2024.106845_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106958","article-title":"Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: the YELLOWSTONE clinical trial program","volume":"122","author":"Feagan","year":"2022","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.ejps.2024.106845_bib0014","first-page":"1","article-title":"Antibiotic perturbations to the gut microbiome","author":"Fishbein","year":"2023","journal-title":"Nat. Rev. Microbiol"},{"issue":"3","key":"10.1016\/j.ejps.2024.106845_bib0015","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.chom.2014.02.005","article-title":"The treatment-naive microbiome in new-onset crohn's disease","volume":"15","author":"Gevers","year":"2014","journal-title":"Cell Host. Microbe"},{"issue":"9","key":"10.1016\/j.ejps.2024.106845_bib0016","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41575-022-00605-x","article-title":"The gut microbiome as a modulator of healthy ageing","volume":"19","author":"Ghosh","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol"},{"issue":"5","key":"10.1016\/j.ejps.2024.106845_bib0017","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3390\/biom11050695","article-title":"Variations in gut microbiome are associated with prognosis of hypertriglyceridemia-associated acute pancreatitis","volume":"11","author":"Hu","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejps.2024.106845_bib0018","series-title":"Xeljanz XR (tofacitinib)","year":"2024"},{"issue":"29","key":"10.1016\/j.ejps.2024.106845_bib0019","doi-asserted-by":"crossref","first-page":"8787","DOI":"10.3748\/wjg.v21.i29.8787","article-title":"Role of the normal gut microbiota","volume":"21","author":"Jandhyala","year":"2015","journal-title":"World. J. Gastroenterol"},{"issue":"7","key":"10.1016\/j.ejps.2024.106845_bib0020","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.cell.2020.05.001","article-title":"Personalized mapping of drug metabolism by the human gut microbiome","volume":"181","author":"Javdan","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejps.2024.106845_bib0021","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijpharm.2017.10.015","article-title":"Ex vivo evaluation of degradation rates of metronidazole and olsalazine in distal ileum and in cecum: the impact of prandial state","volume":"534","author":"Karatza","year":"2017","journal-title":"Int. J. Pharm"},{"key":"10.1016\/j.ejps.2024.106845_bib0022","doi-asserted-by":"crossref","unstructured":"Kim B.R., Shin J., Guevarra R.B., Lee J.H., Kim D.W., Seol K.H., et al. Deciphering diversity indices for a better understanding of microbial communities. 2017 Dec 28;27(12):2089\u201393.","DOI":"10.4014\/jmb.1709.09027"},{"issue":"4","key":"10.1016\/j.ejps.2024.106845_bib0023","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-019-0258-z","article-title":"Gut microbiota-derived metabolites as key actors in inflammatory bowel disease","volume":"17","author":"Lavelle","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol"},{"issue":"5","key":"10.1016\/j.ejps.2024.106845_bib0024","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41569-022-00686-w","article-title":"Changes to the gut microbiota drive the progression of cardiometabolic disease","volume":"19","author":"Lim","year":"2022","journal-title":"Nat. Rev. Cardiol"},{"issue":"2","key":"10.1016\/j.ejps.2024.106845_bib0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41588-021-00992-y","article-title":"Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch Microbiome Project","volume":"54","author":"Lopera-Maya","year":"2022","journal-title":"Nat. Genet"},{"issue":"1","key":"10.1016\/j.ejps.2024.106845_bib0026","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1462-2920.13589","article-title":"Formation of propionate and butyrate by the human colonic microbiota","volume":"19","author":"Louis","year":"2017","journal-title":"Environ. Microbiol."},{"issue":"7698","key":"10.1016\/j.ejps.2024.106845_bib0027","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nature25979","article-title":"Extensive impact of non-antibiotic drugs on human gut bacteria","volume":"555","author":"Maier","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2024.106845_bib0028","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.mib.2017.11.001","article-title":"Systematically investigating the impact of medication on the gut microbiome","volume":"39","author":"Maier","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.ejps.2024.106845_bib0029","first-page":"1","article-title":"The gut microbiota and its biogeography","author":"McCallum","year":"2023","journal-title":"Nat. Rev. Microbiol"},{"issue":"7","key":"10.1016\/j.ejps.2024.106845_bib0030","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/pharmaceutics13071026","article-title":"Machine learning uncovers adverse drug effects on intestinal bacteria","volume":"13","author":"McCoubrey","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2024.106845_bib0031","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jconrel.2022.12.029","article-title":"Colonic drug delivery: formulating the next generation of colon-targeted therapeutics","volume":"353","author":"McCoubrey","year":"2023","journal-title":"J. Contr. Rel"},{"key":"10.1016\/j.ejps.2024.106845_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2021.107797","article-title":"Predicting drug-microbiome interactions with machine learning","volume":"54","author":"McCoubrey","year":"2022","journal-title":"Biotechnol. Adv."},{"issue":"12","key":"10.1016\/j.ejps.2024.106845_bib0033","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.3390\/pharmaceutics13122001","article-title":"Machine learning predicts drug metabolism and bioaccumulation by intestinal microbiota","volume":"13","author":"McCoubrey","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejps.2024.106845_bib0034","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1038\/s41467-020-17956-1","article-title":"Integrated microbiota and metabolite profiles link Crohn's disease to sulfur metabolism","volume":"11","author":"Metwaly","year":"2020","journal-title":"Nat. Commun"},{"issue":"1","key":"10.1016\/j.ejps.2024.106845_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41577-022-00727-y","article-title":"The impact of the gut microbiome on extra-intestinal autoimmune diseases","volume":"23","author":"Miyauchi","year":"2023","journal-title":"Nat. Rev. Immunol"},{"issue":"6","key":"10.1016\/j.ejps.2024.106845_bib0036","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/gutjnl-2015-309184","article-title":"Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery","volume":"65","author":"Mondot","year":"2016","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.ejps.2024.106845_bib0037","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40262-022-01129-y","article-title":"Filgotinib: a clinical pharmacology review","volume":"61","author":"Namour","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2024.106845_bib0038","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijpharm.2011.01.038","article-title":"Application and use of isothermal calorimetry in pharmaceutical development","volume":"417","author":"O'Neill","year":"2011","journal-title":"Int. J. Pharm"},{"issue":"12","key":"10.1016\/j.ejps.2024.106845_bib0039","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s40265-022-01762-8","article-title":"Ozanimod: a review in ulcerative colitis","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ejps.2024.106845_bib0040","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/gutjnl-2016-313235","article-title":"A microbial signature for Crohn's disease","volume":"66","author":"Pascal","year":"2017","journal-title":"Gut."},{"issue":"5","key":"10.1016\/j.ejps.2024.106845_bib0041","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.ejps.2024.106845_bib0042","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4161\/gmic.1.3.12360","article-title":"Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas","volume":"1","author":"Shen","year":"2010","journal-title":"Gut. Microbes"},{"issue":"10","key":"10.1016\/j.ejps.2024.106845_bib0043","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41571-023-00803-9","article-title":"Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors","volume":"20","author":"Simpson","year":"2023","journal-title":"Nat. Rev. Clin. Oncol"},{"issue":"1","key":"10.1016\/j.ejps.2024.106845_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.07.009","article-title":"The gastrointestinal microbiota as a site for the biotransformation of drugs","volume":"363","author":"Sousa","year":"2008","journal-title":"Int. J. Pharm"},{"issue":"10","key":"10.1016\/j.ejps.2024.106845_bib0045","first-page":"3171","article-title":"On the colonic bacterial metabolism of Azo-Bonded Prodrugsof 5-Aminosalicylic acid","volume":"103","author":"Sousa","year":"2014","journal-title":"JPharmSci."},{"issue":"8","key":"10.1016\/j.ejps.2024.106845_bib0046","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jsps.2019.09.011","article-title":"Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice","volume":"27","author":"Sun","year":"2019","journal-title":"Saudi. Pharm. J"},{"issue":"7","key":"10.1016\/j.ejps.2024.106845_bib0047","doi-asserted-by":"crossref","first-page":"e21800","DOI":"10.1371\/journal.pone.0021800","article-title":"REVIGO summarizes and visualizes long lists of gene ontology terms","volume":"6","author":"Supek","year":"2011","journal-title":"PLoS. ONE"},{"issue":"5","key":"10.1016\/j.ejps.2024.106845_bib0048","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.120.000220","article-title":"Absorption, metabolism, and excretion, in vitro pharmacology, and clinical pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor modulator","volume":"49","author":"Surapaneni","year":"2021","journal-title":"Drug. Metab. Dispos"},{"key":"10.1016\/j.ejps.2024.106845_bib0049","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejps.2013.10.001","article-title":"Evaluation of an in vitro faecal degradation method for early assessment of the impact of colonic degradation on colonic absorption in humans","volume":"57","author":"Tannergren","year":"2014","journal-title":"Eur. J. Pharm. Sci"},{"issue":"1","key":"10.1016\/j.ejps.2024.106845_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43705-023-00245-5","article-title":"Optimizing ex vivo culture conditions to study human gut microbiome","volume":"3","author":"Tao","year":"2023","journal-title":"ISME. COMMUN"},{"issue":"10","key":"10.1016\/j.ejps.2024.106845_bib0051","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/nmeth.3589","article-title":"MetaPhlAn2 for enhanced metagenomic taxonomic profiling","volume":"12","author":"Truong","year":"2015","journal-title":"Nat. Methods"},{"issue":"4","key":"10.1016\/j.ejps.2024.106845_bib0052","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41564-018-0337-x","article-title":"The neuroactive potential of the human gut microbiota in quality of life and depression","volume":"4","author":"Valles-Colomer","year":"2019","journal-title":"Nat. Microbiol"},{"key":"10.1016\/j.ejps.2024.106845_bib0053","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejps.2018.09.019","article-title":"Evaluating the clinical importance of bacterial degradation of therapeutic agents in the lower intestine of adults using adult fecal material","volume":"125","author":"Vertzoni","year":"2018","journal-title":"Europ. J. Pharmac. Sci"},{"issue":"02","key":"10.1016\/j.ejps.2024.106845_bib0054","doi-asserted-by":"crossref","first-page":"451","DOI":"10.21474\/IJAR01\/12467","article-title":"The human gut microbiome: considerations toward regulatory testing for drugs and vaccines","volume":"9","author":"Villanueva","year":"2021","journal-title":"IJAR"},{"issue":"8","key":"10.1016\/j.ejps.2024.106845_bib0055","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41564-023-01426-7","article-title":"Human microbiome myths and misconceptions","volume":"8","author":"Walker","year":"2023","journal-title":"Nat. Microbiol"},{"issue":"5","key":"10.1016\/j.ejps.2024.106845_bib0056","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta. Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.ejps.2024.106845_bib0057","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10620-020-06112-w","article-title":"Diet and the human gut microbiome: an international review","volume":"65","author":"Wilson","year":"2020","journal-title":"Dig. Dis. Sci"},{"issue":"1","key":"10.1016\/j.ejps.2024.106845_bib0058","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijpharm.2013.09.007","article-title":"Colonic bacterial metabolism of corticosteroids","volume":"457","author":"Yadav","year":"2013","journal-title":"Int. J. Pharm"},{"issue":"11","key":"10.1016\/j.ejps.2024.106845_bib0059","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3390\/pharmaceutics14112385","article-title":"Ileocolonic-targeted JAK inhibitor: a safer and more effective treatment for inflammatory bowel disease","volume":"14","author":"Yadav","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2024.106845_bib0060","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fphar.2019.00268","article-title":"Gut microbiota-based pharmacokinetics and the antidepressant mechanism of paeoniflorin","volume":"10","author":"Yu","year":"2019","journal-title":"Front. Pharmacol"},{"issue":"7762","key":"10.1016\/j.ejps.2024.106845_bib0061","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","article-title":"Mapping human microbiome drug metabolism by gut bacteria and their genes","volume":"570","author":"Zimmermann","year":"2019","journal-title":"Nature"},{"issue":"28","key":"10.1016\/j.ejps.2024.106845_bib0062","doi-asserted-by":"crossref","first-page":"18465","DOI":"10.1021\/acsomega.1c02591","article-title":"Synthesis and biological evaluation of fingolimod derivatives as antibacterial agents","volume":"6","author":"Zore","year":"2021","journal-title":"ACS. Omega"},{"key":"10.1016\/j.ejps.2024.106845_bib0063","article-title":"Repurposing the sphingosine-1-phosphate receptor modulator etrasimod as an antibacterial agent against gram-positive bacteria","volume":"13","author":"Zore","year":"2022","journal-title":"Frontiers. in. Microbiology. [Internet]"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872400157X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872400157X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:51:13Z","timestamp":1728489073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872400157X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":63,"alternative-id":["S092809872400157X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106845","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the interactions of JAK inhibitor and S1P receptor modulator drugs with the human gut microbiome: Implications for colonic drug delivery and inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106845","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106845"}}